Recruiting

A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes

This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current…

ClinicalTrials.gov IDNCT07112339

PhasePHASE4

Enrollment586

SponsorNovo Nordisk A/S

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Diabetes Mellitus, Type 2

About this study

Interventions

Drug: Insulin icodec — Insulin icodec will be administered as subcutaneous injection.
Drug: Basal insulin analogues — Basal insulin analogues will be administered as subcutaneous injection.

Primary outcomes

Change in glycated haemoglobin (HbA1c) (From baseline week 0 to week 52)

Eligibility information

Inclusion Criteria: * Diagnosed with T2D greater than or equal to (≥) 180 days prior to the day of screening. * Treatment with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening: Metformin, Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs), Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists and Injectable dual glucose-dependent insulinotropic polypeptides (GIP) and GLP-1 receptor agonist. * Need of intensification with basal insulin, as indicated at the discretion of the investigator. * Recorded HbA1c value ≥7% within the last 90 days prior to randomization. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Previous participation in this study. Participation is defined as signed informed consent. * Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method. * Participation (i.e., received any study intervention) in any interventional clinical study within 90 days before screening. * Any disorder which in the investigator's opinion might jeopardize participant's safety.

Study locations

Centricity Research Calgary Endocrinology, Calgary, Alberta T2H 2G4 Canada
Alta Clinical Research at Hermitage Medicentre, Edmonton, Alberta T5A 4L8 Canada
Fraser Clinical Trials Inc., New Westminster, British Columbia V3L 3W4 Canada
Winnipeg Clinic, Winnipeg, Manitoba R3C 0N2 Canada
G.A. Research Associates Ltd., Moncton, New Brunswick E1G 1A7 Canada
Centricity Research Brampton Endocrinology, Brampton, Ontario L6S 0C6 Canada
Centricity Clinical Research Burlington, Burlington, Ontario L7M 4Y1 Canada
Centricity Research Vaughn Endocrinology, Concord, Ontario L4K 4M2 Canada
Medical Trust Clinics, Inc., Courtice, Ontario L1E2J5 Canada
Centricity Research Etobicoke Endocrinology, Etobicoke, Ontario M9R 4E1 Canada

Showing 10 of 75 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.